WO2004033475A1 - チロシナーゼ活性調整剤、その製法、及びそれを含有する外用剤 - Google Patents
チロシナーゼ活性調整剤、その製法、及びそれを含有する外用剤 Download PDFInfo
- Publication number
- WO2004033475A1 WO2004033475A1 PCT/JP2003/013018 JP0313018W WO2004033475A1 WO 2004033475 A1 WO2004033475 A1 WO 2004033475A1 JP 0313018 W JP0313018 W JP 0313018W WO 2004033475 A1 WO2004033475 A1 WO 2004033475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- arbutin
- ester
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/08—Preparations for bleaching the hair
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/46—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical bound to a cyclohexyl radical, e.g. kasugamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- Tyrosinase activity 3 ⁇ 4 its leave, and external medicines including it
- the present invention relates to an external preparation containing tyrosinase inhibitory activity or a thigh and tongue-active compound comprising an active ingredient, which is an active ingredient.
- the present invention also relates to a fiber method for the compound.
- the present invention relates to a novel arbutin ester compound having tyrosinase inhibitory activity, a tyrosinase inhibitor IJ obtained by removing the compound, and an external preparation containing the inhibitor IJ.
- the present invention relates to tyrosinase inhibitor lj, which induces decylenic X as a salt or ester derivative thereof, and an external preparation containing the inhibitor.
- the present invention also relates to an external preparation containing tyrosinase active key and tyrosinase active thigh !!
- the present invention relates to an s ⁇ method for esterification with an enzyme suitable for weaving a compound that can become a ⁇ ⁇ on the thigh. Background technology
- arbutin gel there is known a compound obtained by esterifying phenol of arptin as a depigmenting agent (Japanese Patent Application Laid-Open No. 11-71225 g). Further, as depigmenting cosmetics, compounds in which arbutin is hydroxyesterified at the 6-position are known (JP-A-5-19418l). In addition, lipase is used to esterify arbutin at the 6th position by esterification of arbutin and Ciel biel. The identified compounds have also been described in Yukihiro Bioscience and Biochemistry, 61, 11, pp. 1926—1928, 1997). It has not been clarified yet that the tyrosinase of the J-lebutin invitation or the whitening effect resulting therefrom has been obtained, and a satisfactory level of invitation has yet to be obtained. Did not.
- Pendecylenic acid is an unsaturated fatty acid having 11 carbon atoms and is a component contained in human skin. It can be obtained from castor oil in the early days. It is known that pendilenic acid, its ⁇ X, has its ⁇ action, and its ⁇ X is capable of performing ⁇ Jt washing (JP 2002-114669, g). In recent years, it has been developed as a material for Torehachi-Rose Ester Rider mouth (Japanese Patent Laid-Open No. 2001-278752 ⁇ Ko g3 ⁇ 4 ⁇ Kaigai 5-137994 ⁇ ). However, the use of ismecylenic acid or a salt thereof or an ester thereof to inhibit tyrosinase has never been known.
- sucrose is hardly soluble in these solvents.
- solvents that exhibit solubility eg, DMSO and DMF
- sucrose is dissolved in DMSO in about 40% of 13 ⁇ 4 (advanced carbohydrate) Chemistry and Biochemistry, 27, p.
- the present invention relates to a tyrosinase inhibitory activity 'fX, which comprises a compound having thigh activity as a mechanical component, an oral preparation containing the active ingredient U, and an sst of the compound. It relates to the method of esterification that can be performed.
- an arbutin ester compound having a tyrosinase inhibitory activity significantly higher than that of albutin and having an improved cross-absorbing property are provided.
- the present invention includes the following methods for arbutin ester compounds, tyrosinase activity inhibition, external preparations and purbutin ester compounds.
- R represents a single-aged alkylene group or an arylene group.
- R 2 represents an alkyl group or an aryl group.
- 3 1-7 The arbutin ester compound according to 1-1, represented by H ⁇ (7).
- R represents a single!, An alkylene group, or an arylene group.
- a tyrosinase inhibitor comprising one or more of the arbutin ester compounds according to any one of 1 to 1 to 1 to 10 as an active ingredient.
- a method for producing an arbutin ester compound which comprises a step of esterifying arbutin with a carboxylic acid represented by any of the following H3 ⁇ 4 formulas (11) to (19).
- a mm represents an unsubstituted alkyl group or vinyl group.
- R represents a single-aged arylene group or an arylene group.
- a « ⁇ element and Oki indicate a non-fiber alkyl group or vinyl group.
- R T represents a simple! ⁇ , An aralkylene group, or an arylene group.
- A represents an unsubstituted alkyl group or a vinyl group.
- R T represents a single! ⁇ , An aralkylene group, or an arylene group.
- a ⁇ 3 ⁇ 4K represents a non-resin alkyl group or vinyl group. 3 ⁇ 4 is simply! ⁇ , A It represents a alkylene group or an arylene group. R 2 represents an alkyl group or an aryl group. ] (16)
- A represents a 7j element
- ⁇ represents an unsubstituted alkyl group or vinyl group.
- 3 ⁇ 4, R 3 , R 4 , and R 5 each represent a hydrogen atom, an alkylene group or an arylene group.
- X represents a repeating unit of;! To 6. ]
- a and X represent an unsubstituted alkyl group or vinyl group. Represents a single yarn feed, an alkylene group, or an arylene group.
- a wm represents an unsubstituted alkyl group or Bier group.
- R t is just! ⁇ Represents an alkylene group or an arylene group.
- a ⁇ K is an unsubstituted alkyl group or a Bier group. 3 ⁇ 4 indicates employment, aralkylene group, or arylene group.
- the arbutin ester compound in the present invention is a compound having a spiny group introduced at the 6-position of arbutin. Specifically, they are compounds represented by (1) to (10).
- the arbutin ester compound of the present invention can be formed by subjecting arbutin and carboxylic acids to an esterification reaction.
- the carboxylic acids refer to carboxylic acids and dicarboxylic acids MX.
- the compound of (2) induces arbutin, and the carboxyl of (1 1) below induces it.
- A3 ⁇ 4zK element indicates a non-active alkyl group or vinyl group.
- 3 ⁇ 4 represents a single! ⁇ , An alkylene group, or an arylene group.
- the alkylene group has 1 to 16 carbon atoms, preferably 2 to 8 carbon atoms, and is not particularly limited to a linear, branched, or cyclic shape.
- Ingredients # ⁇ include methylene, arylene alkylene groups of ethylene, ethylethylene, and alkylenes which carry isopropylamine. As an arylene group, phenylene can be mentioned.
- the compound of the formula o) can be synthesized by arbutin core of the carvone m of the following formula (1 2).
- a ⁇ _______ represents a non-key alkyl or vinyl group.
- R represents a simple ⁇ , an alkylene group or an arylene group.
- the alkylene group has 1 to 16 carbon atoms, preferably 2 to 8 carbon atoms, and its shape is particularly linear, branched, or cyclic.
- Examples of the function include an alkylene group which is a methylene group, an alkylene group obtained by converting ethylene, an ethylene group, and an alkylene group which is a component of isopropylene.
- An arylene group is a phenylene group. ?Wear.
- the carboxylic acid derivative represented by the formula (12) includes, for example, methacrylic acid derivative.
- the compound of the formula (4) can be synthesized by allowing arbutin to have a carboxylic acid or dicarboxylic acid derivative of the following general formula (13).
- a mm represents an unsubstituted alkyl group or vinyl group.
- R represents a simple ⁇ , an alkylene group or an arylene group.
- the alkylene group has 1 to 16 carbon atoms, preferably 2 to 8 carbon atoms, and has a linear, branched, or cyclic shape.
- methylene and ethylene the alkylene group of the fiber, ethylethylene, and isopropylene, the alkylene wedge of the diary I, can be mentioned.
- arylene group phenylene can be mentioned.
- Examples of the dicarboxylic acid derivative represented by the formula (13) include oxalic acid, malonic acid, succinic acid, daltaric acid, adipic acid, pimelic acid, speric acid, azelaic acid, sebacic acid, and nonane Aliphatic dicarboxylic acids such as dicarboxylic acid and dodecane dicarboxylic acid, and examples of such compounds include compounds derived from dicarboxylic acids such as (ortho, meta, para) lids, for example, dibiel pudipic acid.
- the compound of the formula (5) can be synthesized by causing arbutin to undergo a dicarboxylic acid of the following formula (14) or a derivative thereof.
- A represents an unsubstituted alkyl group or a vinyl group.
- 3 ⁇ 4 indicates Uni-supply, alkylene group or arylene group.
- the alkylene group has 6 to 21 carbon atoms, preferably 8 to 12 carbon atoms, and its shape is not particularly limited to a linear, branched, or cyclic shape.
- the function can be an alkylene group such as methylene, an alkylene group of ethylene, and an ethylene glycol or isopropylene.
- arylene group phenylene can be mentioned.
- the dicarboxylic acid derivative represented by the formula (14) is specifically: spearic acid, azelaic acid, sebacic acid, nonanedicarboxylic acid, dodecanedicarboxylic acid fatty acid dicarboxylic acid, or ( Dicarboxylic MX such as ortho, meta, para) phthalate can be cited as the compound derived from dicarbone ⁇ 0.
- Dicarboxylic MX such as ortho, meta, para
- the compound of formula (6) can be synthesized by causing arbutin to desorb a carboxylic acid or dicarboxylic acid of formula (15) below.
- a ⁇ j ⁇ element and the position represent an unsubstituted alkyl group or a vinyl group.
- R represents a single group, an alkylene group, or an arylene group.
- R 2 represents an alkyl group or an aryl group.
- the alkylene group has 1 to 16 carbon atoms, preferably 2 to 8 carbon atoms, and is not particularly knee-shaped, such as linear, branched, or cyclic.
- the functions include the alkylene group of methylene and ethylene, and the alkylene group of ethylene and isopropylene. Can be.
- arylene group phenylene can be mentioned.
- R 2 represents an alkyl group or an aryl group.
- the difficulty number of the alkyl group is 1 to: L6, preferably 2 to 8.
- On the ingredient side there are alkyl groups of methyl and ethyl, and alkyl groups of isopropyl wisteria.
- An example of an aryl group is Fujin Fuji.
- Examples of the dicarboxylic acid derivative represented by the formula (15) include oxalic acid, malonic acid, succinic acid, daltaric acid, adipic acid, pimelic acid, speric acid, azelaic acid, sebacic acid, and nonane
- Examples of the dicarboxylic acid derivative represented by the formula (15) include oxalic acid, malonic acid, succinic acid, daltaric acid, adipic acid, pimelic acid, speric acid, azelaic acid, sebacic acid, and nonane
- dicarboxylic acid, dicarboxylic acid from dodecane dicarpone, or dicarboxylic acid from (ortho, meta, para) furan can be mentioned.
- A-OCO-Rr [- R 3 -CH CH-R 4 -] x -R 5 -CH 3
- a and j each represent an unsubstituted alkyl group or a vinyl group.
- R ⁇ , R 3 , R 4 and R 5 each represent; Wl ⁇ r, an alkylene group or an arylene group;
- X indicates a repeating unit of! To 6.
- the alkylene group has 1 to 21 carbon atoms, preferably 2 to 8 carbon atoms, and its shape is linear, branched, cyclic, etc., and is not particularly limited.
- Ingredients include methylene, the alkylene group of ⁇ in ethylene, alkylethylene, and alkylene vinegar, which is responsible for isopropyline.
- Examples of the arylene group include a phenylene group.
- the carboxylic acid represented by the formula (16) or a derivative thereof includes, specifically, decenoic acid, myristoleic acid, pende, senic acid, palmitoleic acid, hexyl, potassium triene acid, Heptadecenoic acid, heptadec'cadienoic acid, oleic acid, linolee, linolenic acid, a?
- the compound of the HIS formula (8) can be synthesized by causing arbutin to induce the carvone of the following formula (17).
- km the symbol represents a non-toluene alkyl group or a vinyl group
- R represents a simple alkylene group or an arylene group.
- the alkylene group has 1 to 16 carbon atoms, preferably 2 to 8 carbon atoms, and its shape is linear, branched, cyclic or the like, and is not particularly limited. Functions include the alkylene group of methylene, the ethylene group, the ethylene group, and the alkylene group of the isopropyl group. As an arylene group, phenylene can be mentioned.
- Examples of the carboxylic acid derivative represented by the formula (17) include compounds derived from piperic acid.
- the alkylene group has 1 to 16 carbon atoms, preferably 2 to 8 carbon atoms, and its shape is not particularly limited to a linear, branched, or cyclic shape.
- Examples of methylene, methylene, ethylene alkylene groups, ethylethylene, and isopropyl are available.
- Examples of the arylene group include phenylene.
- carboxylic acid derivative represented by the formula (18) examples include a compound derived from benzoyl acid ⁇ ′.
- A represents an unsubstituted alkyl group or vinyl group.
- R represents a single feed, an alkylene group, or an arylene group.
- the alkylene group has 1 to 16 carbon atoms, preferably 2 to 8 carbon atoms, and is in a linear, branched, or cyclic shape, and is particularly in the shape of a knee.
- Ingredients include methylene, alkylene groups in ethylene, alkylene, and ethylethylene and isopropylene.
- arylene group phenylene can be mentioned.
- carboxylic acid represented by the formula (19) examples include butyric acid, hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, pentade, camic acid, octrelimetic acid, and heptanedecanoic acid. And stearic acid, arachidic acid, behenic acid, and compounds derived from lignocerin.
- the esterification of arbutin with the compounds represented by the formulas (11) to (19) is performed under an enzyme or a chemical reaction.
- the enzyme catalyst for example, lipase, protease, esterase and the like can be used.
- 3 ⁇ 4 ⁇ 3 ⁇ 4 ⁇ ⁇ such as acids, alkalis, and pyridine derivatives.
- P-toluenesulfonic acid, sodium alcohol Examples include sid, titanium alkoxide, dimethylaminopyridine, body, ⁇ , rooster, pyridine, 4-pyrrolidinopyridine, and dicyclohexylcarbami.
- a method of carrying out an esterification reaction in the presence of an enzyme catalyst is preferred because it has excellent selectivity for the 6-position of arbutin.
- the mystery is 0-100 ° C, preferably 30-50 ° C.
- the period between SJ and S # is 1 to 340 hours, preferably 24 to 170 hours.
- the solvent dimethylformamide, dimethylsulfoxide, pyridine, acetone, or dioxane can be used in combination with two or more solvents.
- the carboxylic acid, dicarboxylic X which is a raw material, can also be used as a solvent for such a derivative.
- the content of arbutin in the medium is 1 to 40% *, preferably 1 to 10%.
- the rate of enzyme conversion is 0.1 to 20%, preferably 0.1 to 1H *%, for Xinjiang.
- the carboxylic acid and dicarbon are preferably 0.5 to 10 moles, preferably 1 to 5 moles per mole of arbutin.
- the time is between 1 and 48 hours, preferably between 1 and 24 hours.
- dimethylformamide, dimethylsulfoxide, pyridine, acetone, dioxane can be used in combination or in combination.
- the concentration of arbutin in the it machine is 1 to 40% by weight, preferably 1 to 10% by weight.
- the use of chemical marauders is 0.1 to 5 ⁇ *%, preferably 0.1 to 1%, based on the medium.
- the carboxylic acid and dicarboxylic acid are preferably added in an amount of 0.5 to 10. mol, and particularly preferably 1 to 5 mol, per mol of arbutin.
- a compound having a free carboxy group at a terminal is inexpensive and have the advantage that water is a by-product in the esterification reaction.
- an ester compound or the like is used as a raw material, a coloring substance is easily generated during the reaction, and purification treatment such as column treatment is required. Such a problem does not occur when a compound having a free hydroxyl group at the end is used.
- an esterification reaction is carried out with arbutin using a compound having a free hydroxyl group at the end as a raw material, water is produced as a by-product, but the esterification reaction is a reversible reaction, so efficient esterification is performed.
- the method of the dehydration treatment is not particularly limited, and known methods and the like can be used. Examples of the method include a method of performing a dehydration treatment under reduced pressure, a method of performing a dehydration treatment by passing dry inert gas, and a method of performing a dehydration treatment by selectively adsorbing water to an inorganic compound such as molecular sieves.
- the reaction scale is small, a method of performing dehydration treatment using molecular sieves is simple and preferable.
- the shape of the molecular sieve is not particularly limited. For example, powder, pellets and the like can be used.
- the amount of molecular sieves used is 0.1 to 50% by weight, preferably 1 to 20% by weight, based on the reaction solution.
- an appropriate arbutin ester compound of the present invention is obtained by subjecting the compound having a hydrophobic group introduced to the 6-position of arbutin from the reaction product to a known appropriate separation and purification treatment.
- separation and purification means for example, known chromatography means such as high performance liquid chromatography and gel filtration chromatography can be used. Conditions such as column type and mobile phase solvent can be selected.
- Separation means such as fractional precipitation based on solubility and solubility can also be used. For example, after extracting and separating the unreacted carboxylic acid derivative in the esterification reaction solution using a non-polar organic solvent, excess water is added to extract and separate the unreacted arbutin, and at the same time, the arbutin ester compound is precipitated.
- the arbutin ester compound of the present invention can be obtained by collecting the precipitated arbutin ester compound after repeating these extraction, separation and precipitation steps, if necessary.
- non-polar solvent examples include cyclohexane, ethyl ether, petroleum ether and the like. Among them, cyclohexane is preferable.
- Inverted water is about 20 times the weight of the raw material arbutin compound.
- the arbutin ester conjugate represented by the formulas (1) to (10) obtained as described above as ⁇ the tyrosinase inhibitor ij can be obtained.
- the alpine ester compounds represented by the above formulas (1) to (10) may be used in one insect or as a mixture of two.
- the tyrosinase inhibitor can be obtained by using the arbutin ester conjugate represented by the formula (1) to (0) as it is or by mixing the arbutin ester conjugate with a fibrous carrier and subjecting the mixture to the following method. Obtainable.
- the tyrosinase inhibitor of the present invention can be added to cosmetics, skin external preparations, medicines, foods, fish and shellfish, and can be stored in foods. For example, it is possible to obtain a compound fc which is combined with a dandy coat and has a whitening effect. Also, in order to prevent foods that are liable to undergo discoloration due to melanin, they can be added to the foods or placed on shelves on the surface. In addition, the tyrosinase inhibition ⁇ ! And an external preparation. In particular, it can be used as an external preparation, preferably as a skin external preparation for whitening.
- the arbutin ester compounds represented by the above-mentioned H3 ⁇ 4 formulas (1) to (10) can be used alone or as a mixture of two or more.
- An external preparation can be obtained by mixing the above tyrosinase inhibitor with a suitable carrier and producing the mixture according to the following method.
- the external preparation may be blended with other difficult components, such as an aqueous component, a powdered humectant, a surfactant, Ito Ito, a thickener, and ultraviolet absorption.
- aqueous component such as a saline, a saline, a saline, a saline, a saline, a saline, a saline, a sulfate, a glycerin, a cream, a milky lotion, a liniment, a lotion and the like.
- the arbutin ester compound ( ⁇ ⁇ is about the effective amount to inhibit tyrosinase. Its content is about 0.001 to 10% by weight, preferably 0.005% by weight, based on the whole external preparation. About 5% by weight.
- the method of application of the external preparation should be, for example, once a day, for stains on the face, neck, arms, and hands, etc., or easily affected areas such as freckles, or easily tanned. Several times, You just need ⁇ flr.
- the arbutin ester compound according to the present invention has improved skin absorbability by introducing a spiny group, and the harmful activity of arbutin and tyrosinase is increased by arbor. Furthermore, the arbutin ester compound according to the present invention has a ⁇ spreading effect, which is considered to be based on a sugar ester structure, a radical scavenging ability, which is thought to be based on a phenolic ffeic acid group, and an esthetic! ⁇ ⁇ ] ⁇ and the surfactant activity that may be related to the HzKffi of the arbutin part.
- the arbutin ester compound of the present invention can be used as a shelf for tyrosinase-inhibited ⁇ or Zhao external preparation for isis quality ⁇ ⁇ ⁇ ⁇ .
- a tyrosinase la or a tyrosinase la or a tyrosinase laminating the salt thereof, or an external preparation containing the tyrosinase, particularly, tyrosinone A whitening agent containing zealous ingredients is scattered.
- the present inventors have conducted extensive studies, and as a result, have found that pendecylenic acid or a salt thereof, or a sugar ester of condecylenic acid has tyrosinase is harmful activity, and have further studied.
- the present invention includes the following tyrosinase inhibitors and external preparations.
- Tyrosina derived from pendicylene acid or its salt or its ester represented by 2-2.
- the tyrosinase according to 2-1 which is a swelling of Rb force S without Zhao group
- Examples of the salts of pendecylenic acid include alkali pot salts such as sodium, potassium, and lithium of pendecylenic acid, alkali dI pot salts such as calcium and magnesium, copper, jetanolamine, ammonium, dimethylamine, trimethylamine, and 2-amino-2.
- alkali pot salts such as sodium, potassium, and lithium of pendecylenic acid
- alkali dI pot salts such as calcium and magnesium, copper, jetanolamine, ammonium, dimethylamine, trimethylamine, and 2-amino-2.
- -Methyl J Salts such as 1,3-propanediol, 2-amino-2-methyl-1-propanol and stearyldimethylamine are available.
- These salts can be used to convert decylenic acid and alkali metal hydroxides, alkaline earth metal hydroxides, other phenolic compounds or amines to water, alcohols (methanol, ethanol, isopropanol, butanol). ), THF, ether, acetonitrile and the like.
- Rb indicates hydrogen or ⁇ H @@ excluding the hydroxyl group).
- R is the bell: ⁇ ,
- Rb_ ⁇ H indicates the occupation, ns, at or a sugar compound such as alcohol.
- sugar represented by Rb—OH examples include glucose, galactose, mannose, fructoose, N-acetyldarcosamine, N-acetylgalactosamine, report, arabinose, xylose, and rhamnose.
- ⁇ Disaccharides such as ⁇ , maltose, lactose, isomaltose, cellobiose, gentiobiose, sucrose, trehalose, isocodypiose, laminaribiose, nigerose, sambubiose, neohesperidose, etc.
- sugar alcohols such as glycerol, erythritol, xylitol, sorbitol, mannitol, and inositol, such as maltotriose, isomalyretotriose, cellotriose, raffinose and gentiotriose.
- Preferred sugars include sucrose, trueno and roasted sugar.
- the decylenic acid ester of the present invention is obtained by converting an ester such as methyl decylenic acid, ethyl decylenic acid ester, etc. under the control of an enzyme ⁇ S. Then, it can be obtained by esterification.
- lipases examples include lipases derived from Notylus and lipases derived from Candida anterctica.
- tyrosinase can be blocked by using a mixture selected from the group consisting of decilenic acid or a salt thereof, or an ester derivative thereof, or by using a mixture of the two as a feature. I can get.
- the tyrosinase inhibitor can be obtained by using one or two kinds of decylenic mx salts or ester derivatives thereof as they are or by mixing them with an appropriate carrier, followed by fine rubbing.
- tyrosinase inhibitors can be used in whitening cosmetics, pharmaceuticals, foods, seafood and gffl, and can be used for food processing.
- tyrosinase inhibition suppresses melanin, it can be added to chemical compounds to make the whitening effect ⁇ ⁇ .
- the foods can be encouraged or exposed to the surface.
- Pendecylenic acid is naturally contained in the skin ⁇ , and its safety I has been established, and it is safe to expect the whitening effect of ⁇ Jt by using food containing pendecylenic acid or a salt thereof. Wear.
- 1 @ X selected from the group consisting of pendecylenic acid or a salt thereof or pendecylene ester represented by the general formula (20) described above.
- 1 @X contains a tyrosinase inhibitor »J containing at least two kinds. It can also be used as an external preparation.
- the external preparation can be used as a skin external preparation, especially as a whitening cosmetic.
- External preparation Can be woven using the Fiber 11 of Japan.
- the external preparation may contain other @@ used for " ⁇ , for example, an aqueous component, a powder, an m, mi enriching agent, an ultraviolet absorbing TO and ⁇ .
- Pendecylenic acid or a salt thereof or a pendecylenic acid sugar ester to be incorporated in an external preparation ⁇ is a tyrosinase-inhibiting fruit.
- ⁇ is a tyrosinase-inhibiting fruit.
- S *% Preferably 0.005-5%, more preferably 0.01-3% by weight, particularly preferably 0.1-1%.
- the form of the external preparation is not particularly limited, and may be prepared in the form of, for example, ointments, creams, emulsions, liniments, and lotions.
- the method of drawing the external preparation of the present invention can be performed, for example, once a day for easy sound or parts such as face, neck, skin spots, freckles, etc., easy to tan, or tan. ⁇ A few times, it should be appropriate.
- the present invention has been found that an ester form of pendecylenic acid and ⁇ »enhances tyrosinase inhibitory activity on rat by an action different from that of arbutin, and provides a tyrosinase: ⁇ ze inhibition! 1 by the action.
- the tyrosinase action indicates the hydroxylation action of monophenol to 1,2-diphenol (catechol) and the oxidation of catechol to 0-quinone, but arbutin Effectively inhibits the hydroxylation of the monophenol, and inhibits tyrosinase by a different mechanism from arbutin by blocking the rosin of the power of the pendant.
- pendilen MX in the present invention is a tyrosinase inhibitor IJ whose salt or ester-attached book is a shelf, and is used as an external preparation, especially as a female external preparation or a whitening cosmetic.
- ascorbin mx comprises a tyrosinase "fffi ⁇ ! I" whose derivative is 3 ⁇ 4 and a tyrosinase activity.
- the present invention includes the following tyrosinase activity promoter and an external preparation containing the tyrosinase activity promoter.
- Ascorbic acid derivative is ascorbin metabolite fatty acid ester, ascorbic acid phosphate ester or its fatty acid ester or a salt thereof, ascorbic acid darcoside or its fatty vein ester, and pscorpinic acid ester or its fatty acid ester Or the tyrosinase activity of thigh IJ according to 3-1 which is at least one selected from the group consisting of:
- An external preparation comprising the tyrosinase activity inhibitor according to 3-4.3-1 or 3-2.
- ihX is an external preparation for improving gray hair.
- Rinkuro is a topical male preparation for the treatment of male anti-vitiligo.
- the tyrosinase activity enhancer is tyrosinase tongue iS ⁇ ij containing ascorbic acid as an active ingredient, and the content of ascorbic acid is 0.001 to 1% of the total external preparation.
- the external preparation according to any one of to 3 to 5.
- 3-8. A tyrosinase active iSi agent, wherein the tyrosinase activity promoter is at least one compound selected from the group consisting of ascorbic acid phosphate and ascorbic acid darcoside, 3.
- the external preparation according to any one of 3-3 to 3-5, wherein the content of the compound is from 0.003 to 3 to 5% by weight of the whole external preparation.
- the tyrosinase activity of the present invention is triggered by ascorbic acid and Z or ascorbic acid.
- ascorbine release / or ascorbine may be used for one kind of insect, or two kinds of pulp may be used in combination.
- Ascorbic acid is a water-soluble in vivo antioxidant, also called vitamin C, which leaks to various targets in various places in the body or cells. Ascorbic acid has L— # D—, but L is used as the ascorbic acid of the present invention.
- ascorbic acid attraction refers to one in which at least one of the 2, 3, 5, and 6 positions of ascorbic acid is placed in the furnace and has a tyrosinase activity. Used.
- ascorbic acid derivatives include ascorbine transesterified fatty acid ester, ascorbic acid phosphoric acid ester or fat fat ester or salt thereof, ascorbic acid glycoside or fat J! Mat ester, and buscorbic acid salt Esters, their fatty esters, their salts, etc.
- ascorbic acid is very powerful.
- Fat used in ascorbic acid induction specifically, ascorbic acid fat, fatty acid ester of ascorbic acid phosphate ester, fatty acid ester of ascorbic acid glucoside, and fat used in fatty ester of scorbic acid ⁇ ester Acids include saturated or unsaturated fats and fats, and ⁇ includes fat tree fat dogs, and ⁇ ⁇ is not particularly specified.
- the return number of the oily thigh is particularly P, but usually the return number is 1 to 24, preferably 8 to 20 and more preferably 10 to 18.
- Ascorbyl transesterified ester is a compound obtained by esterifying at least one hydroxyl group at 2, 3, 5 and 6 positions of ascorbic acid with an internal fiber.
- ascorbic acid 6-norremy 5 ⁇ ⁇
- ascorbic acid 1,2,6-noluminate ascorbic acid 16-stearate and the like can be mentioned.
- ascorbic acid phosphoric acid ester examples include ascorbic acid 12-phosphate ester in which phosphoric acid is esterified to the 2-phenylene group of ascorbic acid.
- Ascorbic acid phosphate salt, ascorbic acid phosphate salt, and functions such as alkaline pot salt and alkaline earth pot salt can be used. More specifically, ascorbic acid-2-sodium phosphate and magnesium ascorbic acid-12-phosphate can be climbed.
- Examples of the fatty vein ester of ascorbic acid phosphoric acid ester include compounds obtained by esterifying the hydroxyl group of ascorbic acid phosphoric acid ester into scabs, for example, scorbic acid-2-phosphoric acid 1-6-norrelimitate, ascorbic acid 1 2 —Phosphate 6-laurate, ascorbate 12-phosphate-6-stearate.
- Salts of fatty acid J3 male ester of ascorbic acid phosphate include, for example, ascorbic acid 12-phosphate 16-palmite sodium salt, ascorrebate 12-phosphate 16-laurate Can be covered with magnesium salts.
- Ascorbic acid darcoside includes, for example, ascorbic acid-21-dalcoside in which dulose is darcoside-bonded to the hydroxyl group at position 2 of ascorbic acid.
- Fatty esters of ascorbic acid darcoside include compounds obtained by esterifying sescorbic acid darcoside with liposide, such as cescorbic acid 1-2-darcoside 16-palmitate, ascorbic acid-2-dalcoside 6-stealeitol, Ascorbic acid 1-2-darcoside 16-laurate.
- examples of the ascorbic acid ester include ascorbic acid-2-ester, in which sulfuric acid is esterified to the 7-position group at the 2-position of ascorbic acid.
- salt of ascorbic acid ester examples include salts of ascorbic acid sulfate, specifically, alkaline pot salts and alkaline earth metal salts.
- Fatty acid esters of ascorbic acid sulfate include fatty acid ester of 7 ascorbic acid sulfate ester which is esterified to 0! ⁇ !, for example, ascorbic acid-2-sulfonic acid 6-palmitate, ascorbic acid 2-Sulfuric acid 6-stearate, ascorbic acid 2- 2- ⁇ -6 laurate
- ascorbin transesterification fatty acid ester ascorbic acid phosphate, fatty acid ester of ascorbic acid phosphate, darcoside ascorbic acid, and fatty acid ester of ascorbic acid glucoside are Wei-kapaku, Tiroshi: ⁇ It is preferable because it has excellent activity.
- An excellent tyrosinase activity promoting effect can be obtained by using ascorbic acid, Z or ascolevin, which are effective amounts of the tyrosinase activity promoting agent in the present invention.
- Tyrosinase uses tyrosine as a substrate and touches the hydroxylation reaction and the oxidation of DOPA that occurs.However, it acts as ascorbic acid or ascorbic acid-derived ice during the Fentination reaction, thereby exerting tyrosinase activity. It is considered.
- the tyrosinase activity containing the ascorbic acid and ⁇ or ascorbic acid derivative is primarily absorbed and 3 ⁇ 41 rejected, and acts on melanocytes to exhibit excellent melanin production.
- the tyrosinase activity promoter of the present invention uses ascorbic acid and Z or a derivative of ascorbic acid as they are, and It can be obtained by mixing with a suitable carrier and adjusting according to the elimination of ⁇ 0.
- An external preparation can also be obtained by using the tyrosinase activity ⁇ 1 agent as a component.
- External preparations can also be obtained by using the tyrosinase activity ⁇ 1 agent as a component.
- the preparation has an excellent tyrosinase activity and a melanin-producing iSi action, and can be used as, for example, a g ⁇ ffl external preparation or a male external preparation. In addition, it can be used as a transdermal treatment for Parkinson's disease, which acts on melanin ⁇ spores such as the Nakazuki radish.
- an external preparation for the head specifically, a l ⁇ ffi external preparation for preventing gray hair, improving gray hair, or visualizing the source of color is used.
- topical topical preparations is not particularly kneeling, and can be used as, for example, shampoo, rinse, hair conditioner, hair pack, hair liquid, hair tonic, hair spray, shelving, hair dye, etc.
- the form of the external preparation can be used in various forms such as liquid form, tanada, cream form, gel form, m, and the like. It can be used as an external preparation for anti-vitiligo treatment, skin tanning or skin blackening.
- the types of external preparations for the skin are not particularly kneeling, such as lotions, emulsions, cleansing creams, nutritional creams, makeup base creams, foundation creams, body lotions, hand creams, red creams, Use as a body soap, body sham.
- the form of the external preparation is not particularly limited, and can be used in the form of a lotion, liquid, cream, gel, milky dog, or solid form.
- the topical preparation may include any auxiliaries or publicly known aids to enhance the efficacy of tyrosinase activity ⁇ ⁇ ! 1 ⁇ 5 .
- auxiliaries such as calenapa, wax, mokurou, oils such as olive oil, jojoba oil, etc. J3 ⁇ l, octyl decyl balmitite, neopentyl glycol diisooctane Ester, stearic acid, palmitin, high-grade alcohol, cetyl alcohol, stearyl alcohol, etc., high-grade alcohol, nonion, anion, cation, and surface action of both types!
- the content of the tyrosinase activity is 0.0000 to 1 011% of MJt, preferably 0.0000 to 0.1, based on the total external preparation. % By weight.
- the amount of tyrosinase activity relative to the total external preparation is 0.0 0000 1-: L 0S *% @ J3 ⁇ 4, preferably 0.0 001-0.1 It is a basket% body.
- the tyrosinase activity promoter is a tyrosinase activity promoter containing ascorbic acid as an active ingredient
- the content of ascorbic acid is about 0.001 to 1% by weight, preferably 0. It is about 0.1 to 1% by weight, more preferably about 0.01 to 1% by weight, and still more preferably about 0.1 to 1% by weight. Since ascorbic acid is hardly absorbed from the skin, when the intracellular concentration is considered to be an effective amount of 10 to 4 M or lower, it is considered that ascorbic acid in the entire tyrosinase activity promoter composition The concentration is considered to be about 0.001 to 1% by weight.
- the tyrosinase activity enhancer is a tyrosinase activity enhancer containing at least one compound selected from the group consisting of ascorbic acid phosphate and ascorbic acid glucoside
- the content of the compound is 0.001 to: L: about 0% by weight, preferably about 0.01 to 10% by weight, more preferably about 0.01 to 1% by weight, more preferably about 0.1% by weight, based on the whole preparation. About 1% by weight.
- Ascorbic acid phosphates and dalcosides are more stable than ascorbic acid and have increased skin permeability or absorption compared to ascorbic acid.
- the tyrosinase activity promoting agent when 1 0 one 2 M ⁇ L 0 one 4 M about considered effective amount of activating effect that the intracellular seen, the ⁇ ascorbic acid phosphoric acid ester or Darukoshido body, the tyrosinase activity promoting agent
- concentration in the whole composition is considered to be about 0.001 to 10% by weight.
- the tyrosinase activity promoter is composed of fatty acid ester of ascorbic acid, fatty acid ester of ascorbic acid phosphoric acid ester JI, and fatty acid ester of scorbic acid darcoside, and at least one compound selected from the group consisting of ⁇ "Ze activity ⁇ 1 agent: ⁇ , the content of the compound is 0.0000 to 0.1% by weight of the total amount of the external preparation, preferably 0.001% ⁇ 0.1% away, more preferably 0.001 ⁇ It is about 0.1% by weight, more preferably about 0.01 to 0.1% by weight.
- Ascorbin mx is ascorbin's hard-fat ester, which is considered to be getting higher. This order, the ⁇ 3 ⁇ 4 intracellular ⁇ ! Is considered the amount 1 0 one 4
- ascorbin is the tyrosinase activity of the fatty acid ester induced by ascorbic acid ⁇ ⁇ ij in the whole WftJ?
- tyrosinase activity iSi action or tyrosidase activity exhibiting melanin production®i action is defined as ⁇ for ascorbic acid and Z or ascorbinate, which are safe and have low i3 ⁇ 4i cost. External preparations are used.
- Ascorbic acid or an ascorbic acid derivative has been used as a melanin production inhibitor.
- ascorbic acid and / or ascorbic acid induces ⁇ , tyrosin: ⁇ ze activity and thyros: ⁇ ze activity. It has been found that it can be used as a fibrous agent having an action of 1.
- the tyrosinase activator according to the present invention is safe, inexpensive and difficult to achieve, and exhibits excellent tyrosinase activity efficiency and melanin production.
- An external preparation containing the tyrosinase activity iS ⁇ lJ also has an excellent tyrosinase activating effect and a melanin production key effect.
- tyrosinase activity IX can be used in the fields of ⁇ , ⁇ and ⁇ for the purpose of melanin fiber.
- it can be used on shelves as an external preparation such as ihffl for preventing gray hair and for improving white hair, and as an external preparation for Zhao such as ⁇ goku bffl and ⁇ 's anti-vitiligo treatment.
- the fourth preferred form of the present invention includes the method of esterification with a saccharide ⁇ in a nucleoside-soluble solvent ⁇ .
- lipase type A derived from Candida annica cutica (Candariaantarctica) has high activity in an aprotic medium. Furthermore, it was also found that in experiments using sucrose as a quality, particularly high fibrous properties were obtained, and based on these findings, we conducted intensive studies.
- the present invention includes the following $ S ⁇ method of esterification.
- Candida antarctica (Candida antarctica) Under a lipase type A origin, in a non-protonic leaking medium, a compound with ⁇ T and a Ji effect «X The method of the beauty salon, the Sl ⁇ method of making the beauty salon.
- the aprotic shelf solvent is any one selected from the group consisting of dimethylformamide, dimethylsulfoxide, and a mixture of dimethylformamide and dimethyloxide. ⁇ Law.
- the compound having a hydroxyl group is a compound, a nucleoside, a sugar alcohol, or an amino ⁇ ;
- the compound having a hydroxyl group is a saccharide
- Rc represents a fatty acid having 1 to 24 keys.
- the weaving method of the esterified product according to the fourth aspect is that the lipase type 8 derived from Candida antarctica (C and i da antarctica) has a non-proton It is assumed that a compound having seven furnaces and a fatty acid “X” are esterified in the medium of the aritanium medium.
- the esterification means synthesis of an ester, and includes an esterification reaction and an ester. Specifically, the reaction between carboxylic acid and alcohol (R'-COOH + R "-OH ⁇ R'-COO-R”), the reaction between ester and alcohol (R'-COO—R ⁇ + R "' -OH ⁇ R'-COO-R '").
- R'-COOH + R "-OH ⁇ R'-COO-R" the reaction between ester and alcohol
- a lipase type A derived from Candida antarctica is used as the enzyme leak.
- Lipase from Candida da ant arc tica (Candida da ant arc tica), Thailand
- the present inventors have found that, among these, lipase type A is an excellent enzyme having a high activity in an aprotic organic medium.
- Lipase A can be obtained from lipase after fermentation, for example, by gel filtration. It can also be produced using recombinant DNA sources, depending on the gene encoding lipase A.
- the lipase type A is 0.1 to 20% of the solvent, preferably 0.1 to: L 0% @ JS.
- the reaction & g for the reaction using lipase type A can be set as ⁇ right arrow over (10) ⁇ : usually 10 to 100 ° C. ⁇ , preferably 30 to 50, and is Si.
- Aprotic organic solvent usually 10 to 100 ° C. ⁇ , preferably 30 to 50, and is Si.
- the process of the present invention is performed in an aprotic I live leaking medium.
- non-protonic raw medium is not particularly limited.
- dimethylformamide, dimethylsulfoxide, or a mixed solution of dimethylformamide and dimethylsulfoxide is preferred in view of the catalytic contact point.
- dimethyl sulfoxide is preferable.
- the ratio of the mixed solvent may vary, the ratio of the dimethyl sulfoxide is preferably at least 60%, more preferably at least 80%.
- a compound having at least one hydroxyl group is particularly effective.
- a nucleoside a sugar alcohol, an amino acid having a hydroxyl group, or the like.
- saccharides include natural sugars such as occupations, light garments, polysaccharides, and their hydrolyzable products.
- these fibers can be used, for example, amino sugars, and long sugars.
- these simulated materials may be used.
- Examples of simple escarpment include compounds having 2 to 8 carbon atoms, such as glucose, fructose, mannose, galactose, and ascorbic acid, preferably compounds having 5 to 7 carbon atoms.
- the conditions include, for example, trehalose or its: ⁇ mouthpiece, sucrose (sucrose), maltose, cellobiose, lactose, etc., raffinose etc., 31, mannooligosaccharide, maltooligosaccharide, etc. I can do it.
- polysaccharide examples include cellulose, starch, chitin, chitosan, hyaluronic acid, mannan, xylan, and pullula.
- the nucleosides include, for example, compounds in which deoxylipose or lipose is added to each of adenosine, guanosine, cytosine, thymine, and peracyl ass, or a derivative thereof (such as a book).
- sugar alcohols examples include glycerol, erythritol, arabitol, xylitol, sorbitol, mannitol, and wild boar.
- amino acids having a hydroxyl group examples include serine, threonine, and tyrosine. It is.
- One of these compounds may be used in a worm or two or more of them may be used in combination.
- the concentration of the compound having a hydroxyl group in the reaction solvent is from 0.01 to 1 M, preferably from 0.1 to 0.5 M. Fat j »X is the invitation
- the type of the fatty acid or the derivative thereof used in the present invention can be set as desired as desired.
- saturated or unsaturated fatty monocarboxylic acids, dicarboxylic acids, and polycarboxylic acids containing three or more carboxylic acids can be used.
- the number of wisteria of Fatsatsu is usually 1-24, preferably 6-18.
- Fatty monocarboxylic acids include, for example, cabronic acid, sorbic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitoleic acid, palmitic acid, stearinic acid, isostearic acid, oleic acid, rhinoic J , Linolenic acid, pennodecanoic acid, eicosanoic acid, docosanoic acid, docosenoic acid, arachidonic acid, ricinoleic acid, and dihydroxy stearin.
- palmitic acid, stearic acid, cabronic acid, potassium chloride, and lauric acid are preferred.
- dicarboxylic acid examples include adipic acid and sebacic acid.
- a saturated or unsaturated aliphatic dicarboxylic acid, particularly adipic acid is preferable since a polymerizable monomer can be obtained as a divinyl ester.
- fatty acid ester examples include fatty acid bier ester, lower alkyl ester, and halogenated alkyl ester.
- vinyl ester is preferable because it is excellent as an ester thigh!
- lower alkyl used herein means a linear or branched alkyl group having 1 to 6 carbon atoms
- halogenated fiber alkyl means at least one halogen atom (fluorine atom). , Leaked atoms, difficult atoms, etc.).
- Specific examples of Natsusatsu nada include the above-mentioned Pis ester, methyl ester, ethyl ester, trifluoroethyl ester and trichloroethyl ester, divinyl ester of adipic acid and sebacic acid.
- biel caproate vinyl caprylate, vinyl laurate, biel myristate, vinyl lumimitate, vinyl stearate, vinyl divinyl decylate, vinyl oleate, and divinyl adipate preferable.
- these fats or their derivatives may be used in one type of job, or two or more types may be used in combination.
- these fats J «X may be derived from water-substitutes, tombs of Ripulonil, a fuel group, and a halogen wisteria substituent.
- the amount of the above-mentioned lipoma or its invitation can be set, but it is usually 1 to 10 moles, preferably 1.2 to 4 moles, for 1 mole of the compound having a hydroxyl group.
- Sucrose ester 1 to 10 moles, preferably 1.2 to 4 moles, for 1 mole of the compound having a hydroxyl group.
- sucrose and fat are induced in a non-proton f raw disc medium
- the compound power represented.
- Rc represents the number of aliphatic Ji layers having a number of 1 to 24.
- the aprotic organic solvent the solvent that has been touched can be used with difficulty, but dimethylformamide, dimethylsulfoxide, and dimethylformamide And dimethylsulfoxide. Particularly, dimethyl sulfoxide is preferred.
- the fat or its attraction the compounds exemplified as nervous tumors or its attraction can be traversed as required. In particular, divinyl adipate, vinyl propyl acetate, vinyl propyl phosphate, laurin Vinylate, pinyl palmitate, and vinyl stearate are used with respect to reactivity.
- sucrose esters that have been put into practical use have been prepared by chemical methods, and are mixtures of mono-, di-, and triesters.
- the fatty acid ester is woven into the "" tough group at the 1 ', 6 and 6' positions of sucrose. For this reason, the ⁇ 7 ⁇ property is low, and the amount of water-soluble raw material in the sintering process is sufficient.
- sucrose ester esterified to a No. 7 carrying base only in a high-strength steel without using a shelf process.
- sucrose ester in which the hydroxyl group at the 2-position obtained by the method of the present invention is selectively esterified can be used in the fields of foods, cosmetics, shampoos, rinses, sucrose, and fiber washing IJ. It can be used as such.
- an esterification can be efficiently obtained even when a compound having high water solubility is used as a raw material.
- the i method of the esterified compound according to the present invention is used for TO for the esterified compound ⁇ i which requires a strong reaction due to an enzyme.
- Fig. 1 shows the time course of the arbutin conversion rate (reaction rate) measured by adding molecular sieves and adding arbutin ester to $ 3 ⁇ 4i by varying the concentration of molecular sieves. It is a drawing showing the result of having performed. The analysis was performed using HPLC.
- Fig. 2 shows the results of the observation of the appearance of arbutin transi (i), with the addition of molecular sieves and S3 ⁇ 4t of the arbutin ester, with various changes in the arbutin ass. ⁇ . The analysis was performed using HPLC.
- Figure 3 shows the results obtained with arbutin and Example 1 against mushroom tyrosinase. 1 is a drawing showing the results obtained by measuring the inhibitory activity of the obtained arbutin ester compound.
- FIG. 4 is a drawing showing the results obtained by using mouse melanoma cells to produce arbutin and the arbutin ester compound obtained in Example 1 for melanin production.
- FIG. 5 is a graph showing the tyrosinase inhibitory activity of pentadecylenic torehylose ester when using pyrocatechol or phenol as a substrate, as performed in Examples 2-1 and Examples 2-14.
- -OCatechol (catechol) used pyrocatechol as a substrate
- ⁇ ,-• -Phenol (phenol) shows the age of phenol using phenol as a substrate.
- FIG. 6 is a graph showing the tyrosinase inhibitory activity of arbutin in catechol or phenol used as a substrate in Comparative Examples 2-1 and 2-3.
- -OCatechol catechol
- phenol pyrocatechol
- phenol phenol
- FIG. 7 is a diagram showing the I-side of the tyrosinase inhibitory tongue when catechol used in Examples 2-1 and 2-3 and 2-2 was used as a substrate.
- FIG. 8 is a diagram showing S3 ⁇ 4 of the ostium synthetase inhibitory activity obtained when phenol was used as a substrate in comparison with Examples 2-5 and! J2-4.
- FIG. 9 is a graph showing the inhibitory activity of arbutin and pendecylenic acid on tyrosinase.
- Arbutin injection inhibits the reaction of monophenol, and the induction of pendecylene acid inhibits the oxidation of diphenol.
- Figure 10 shows the results of examining the promotion rate of tyrosinase activity of ascorbic acid and ascorbic acid derivatives.
- Figure 11 shows that DMF or DMS0 containing 0.25 ⁇ sucrose and 1M divinyl adipate dissolved in Lipase A (CAL-A) derived from L. antarctica or Reno from L. antarctica. Awake showing mouth type B (CAL-B) and showing a change to the beauty JW book after 24 hours at 40 ° C.
- CAL-A DMF or DMS0 containing 0.25 ⁇ sucrose and 1M divinyl adipate dissolved in Lipase A
- CAL-B Awake showing mouth type B (CAL-B)
- FIG. 12 shows that Candida antactica-derived lipase type A (CAL-A) is injected into a mixed solution of DMF and DMSO containing sucrose (0.125M) and divinyl adipate (0.5M),
- FIG. 3 is a drawing showing ⁇ to sucrose ester when the mixing ratio of DMF and DMS O was changed and the drinking time was 30 and 24 hours and 30 hours.
- B in Fig. 12 shows that Candida antactica-derived lipase type A (CAL-A) is injected into a mixed solution of DMF and DMSO containing sucrose (0.125M) and divinyl adipate (0.5M)
- FIG. 3 is a drawing showing ⁇ to sucrose ester when the mixing ratio of DMF and DMS O was changed and the drinking time was 30 and 24 hours and 30 hours.
- FIG. 12 shows that lipase type B (CAL-B) derived from the force of angiotactite force was mixed in a mixture of DMF and DMSO containing sucrose (0.125M) and divinyl adipate (0.5M).
- FIG. 3 is a drawing showing the transformation to sucrose ester when added and changed the mixing ratio of DMF and DMSO and kept at 30 ° C. for 7 days.
- Figure 13 shows that maltose 0.25M and divinyl adipate 1M were dissolved in dimethylformamide (DMF), dimethylmethy J-resulfoxide (DMS0), and N-methylpyrrolidone (NMP), respectively.
- DMF dimethylformamide
- DMS0 dimethylmethy J-resulfoxide
- NMP N-methylpyrrolidone
- FIG. 3 is a drawing showing that lipase type A (CALA) and type B (CALB) derived from da ant arc tica) were each spouted in an amount of 10 mg ml and stirred at 40 ° C. for 24 hours to form an ester form.
- CALA lipase type A
- CALB type B
- Vinyl decenoate 6-0-decenoyl arbutin 92 Vinyl oleate 8-0 One-year-old yl arbutin 82 Piha, vinyl phosphate 6-0-Pivalinoyl arbutin 75 -0 Benzonoyl arbutin 72
- the molecular sieves 4A placed in the flask was heated in a microwave oven for about 1 minute, and immediately thereafter, cooled down to room temperature in a vacuum hood. It was found that only the monoester was ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ S S S ⁇ 4 4 4 4 4 4 4 4 4 4 4 4 And 2.5 ml of water were added, and 5 ml of hexane was leaked out to extract un-J ⁇ pentadecylenic acid into the hexane layer.
- the yield of the obtained ester compound was 91%. Also, the method of the example was simple and easy to purify with a silica gel column. Difficult case 1-6
- Arbutin was 55 mg to 872 mg (0.05 to 0.8 ⁇ ), and 10-pandecylenic acid was 4 ⁇ I * of arptin.
- the enzyme was used in the same manner as in Difficult Example 1-6.
- the time course of arbutin was measured by HPLC analysis. The result is shown in figure 2.
- the more mysteries of arbutin the more they were evacuated, and they showed a flat straight line at 0.6 mm or more.
- Consultation 1 Tyrosine synthase inhibitory activity using proline
- the tyrosinase inhibitory activity of the arbutin ester compound of the present invention was measured by a method using proline (Analytical Biochemistry, 179, 375-381, 1989).
- proline Analytical Biochemistry, 179, 375-381, 1989.
- 41 ml were placed in a Pmgffl cuvette.
- the cell pellet was suspended in a wet dilatation cell pellet in MilliQ water, and the total dissolved volume was set to 700 1. This was sonicated for 15 min, followed by 700N 6N 7 layer. The dagger sodium water was mixed with the syrup, and the cells were lysed and the cells were lysed, and the measurement was carried out at (405M). It was determined as an average. Melanin productivity per cell was expressed as A405 I / D / it / mm ( ⁇ g). Assuming that the melanin per cell per arbutin was not stimulated as 100%, we asked for the key arbutin indecilenic acid or arbutin for melanin production. Fig. 4 shows the results.
- arbutin pendecylenic acid showed about 100-fold higher inhibition than arbutin.
- the tyrosinase inhibitory activity of pendecilene ester was determined by the method using proline (Analytical Biochemistry, 179, 375-381, 1989). ⁇ ⁇ 7.5 ⁇ L of 0.1 M phosphate buffer dissolved in 0.1 M phosphate buffer, 40 ⁇ l of 0.749 M L-proline, 40 ⁇ l of pyrocatechol of 0.037 ⁇ l, and 1.41 ml of various trehalose monosuccinic acid esters (Tre-Unde) I took it in the suction cuvette.
- tyrosinase IS-toxic activity of trehalose di-decylenate (Tre-di-Unde) was examined in the same manner as in the method described in Example 2-1, and it was confirmed that the tyrosinase activity was not inhibited.
- Fig. 7 shows the results. Difficult case 2-4
- phenol is hydroxylated by tyrosinase, and at this time, hydrogen is represented by ⁇ .
- Pyrocatechol is oxidized by tyrosidase to form orthoquinone.
- the tyrosidase activity was measured by measuring the amount of orthoquinone under proline.
- the tyrosinase activity promotion rate was represented by what percentage of tyrosinase activity was inhibited or promoted when no test substance was added.
- a tyrosinase activity promotion rate of 100% indicates that the tyrosinase activity is twice as high as when no test substance was added.
- L-ascorbic acid Japanese drug number: 016-04805
- Ascorbin ⁇ ⁇ can be expressed as follows: ascorbin ⁇ "2-glucoside (sum number: 074-04581), ascolevic acid monophosphate phosphate (ascolevic acid phosphate magnesium salt (sum number: 013) — 12061) and ⁇ ) and ascorbic acid-161 palmitate (sum ⁇ number: 011-13662) were used.
- Fig. 10 shows the measurement results. As shown in FIG. 10, Asukorupin acid, 10- 3 M ⁇ 10- but key tyrosine Na one zero of ⁇ was seen in the, tyrosinase one Ze reversed in the following riddle 10 one 4 M Activity ⁇ action was observed.
- Difficult Example 1 Candidaan tactica-derived lipase type A (Ch i razyme, L5, 1 yo: CAL-A) was replaced with Candidaan citrus lipase type B (Chir azyme, L2). , 1 yo: CAL-B) ⁇ ⁇ .
- FIG. 11 shows the results of modification of the ester form in Example 4-1 and Comparative Example 4-1. As shown in FIG. 11, it was revealed that lipase type A showed higher activity in DMF and DMS0 than lipase type B. Especially in DMS0, the effect was ( ⁇ . Difficult case 4—2
- FIG. 12 shows the results of the modification of the ester in Example 4_2 and Comparative Example 4-2. As shown in FIG.
- lipase type A (CAL-A) exhibited higher activity in a mixed solvent of DMF and DMS0 than lipase type B (CAL-B). In particular, lipase type A was more effective as the amount of DMS0 mixed increased. Difficult case 4 1 3
- Example 43 Candida antarctica-derived lipase type A (Chir azyme, L5, 1 yo: CAL-A) was replaced with Candida antarctica-derived lipase type B (Chir azyme, L2, 1). yo: Using CAL-B) performed the same operation and examined ⁇ W of the ester form.
- FIG. 13 shows the results obtained by examining the conversion of the ester in Examples 13 and 14 and Comparative Examples 4-3.
- the lipase type A differs from type B in maltosis: ⁇ , and in each aprotic 3 ⁇ 4W medium, lipase type f & f was produced in each aprotic 3 ⁇ 4W medium.
- Candida antarctica-derived lipase type A (Chirazyme, L5, 1 yo: CAL-) was added to 150 ml of dimethylformamide in which 6.42 g (0.125 M) of sucrose and 10.7 g (0.5 M) of vinyl carboxylate were dissolved. A) 50 Omg was added to suspend. I told the enzyme ⁇ JS night at 30 o'clock at 130 rpm. ⁇ ) At night, HP LC analysis was performed under the same analysis conditions as in Difficult Example 4-1. He found that sucrose was almost completely converted to its ester form.
- Candidaan Yuichi Kutika lipase type A (Chirazyme, L5, 1 yo: CAL) in 150 ml of dimethylformamide containing 6.42 g (0.125 M) of sucrose and 12.8 g (0.5 M) of vinyl acetate. -A) 50 Omg was added to suspend. The enzyme iS was left overnight at 30 ° C and 130 rpm. On the night of lS, we performed HPLC analysis on the same cases as in Example 4-1 and found that almost all sucrose was converted to beauty treatment books. m ⁇ ⁇
- Candida antarctica-derived lipase type A (Chirazyme, L 5, 1 yo: CAL) was added to 150 ml of dimethylformamide in which 6.42 g (0.125 M) of sucrose and 15 g (0.5 M) of vinyl propyl phosphate were dissolved. -A) 50 Omg was added and suspended. The ⁇ ⁇ «was kept at 30 ° C at 130 rpm for 3 days. For J ⁇ night, HPLC analysis was performed on the same samples as in Example 4-1. We found that almost all of the sucrose was converted to esteri books. The product was processed in the same manner as in Difficult Example 4-5 to obtain 6.0 g (yield: 64%) as white crystals. 13 C NMR analysis shows that sucrose with a caprin plant bell introduced at the second position of sucrose It has been certified.
- Example 418 in place of Candida ant arc tica lipase type A (lipase A) derived from Candida ant arc tica, Muco javanicus (Mucor javanicus) originated lipase (lipase ⁇ M) and Aspergillus Using lipase (lipase A,) from germ (Aspergillus niger) and lipase (lipase AY) from Candida cylindracea 3 ⁇ 4W Examined.
- lipase type A lipase type A
- Muco javanicus Muco javanicus
- lipase ⁇ M Aspergillus
- Table 4-1 shows the conversion of sucrose 2-vinyladipate using each lipase in Example 14-18 and Comparison! 14_4.
- a tyrosinase activity preparation containing a compound having a tyrosinase inhibitory activity or a promoting activity as an active ingredient, and an external preparation containing a window-closing agent are provided.
- the compound is held by the law.
- J are provided.
- tyrosinase reversal and external preparations containing the reversal which use pentadecylenic acid or a salt thereof or an ester derivative thereof as an active ingredient, are eliminated.
- a tyrosinase activity promoter containing ascorbic acid or a derivative thereof as an active ingredient.
- the above-mentioned tyrosinase inhibitor I ⁇ relates to an enzymatic esthetic JW danigata method which can be applied to a fiber of a compound which is a mechanical component of a pharmaceutical agent.
- the tyrosinase is more harmful to arbutin than the arbutin by introducing a spiny group into the 6-phenylene group of arbutin.
- the compound is improved in absorbability by introducing the M biogroup.
- a sugar ester machine a porphyry ore that is thought to be based on phenol; a radical that is thought to be based on a phenol penne group It also has a scavenging ability and a surfactant activity that is thought to be based on the properties of esthetics / ⁇ and arbutin.
- arbutin effectively inhibits the former monophenol, Fenney ras, and its mechanism of induction of pentadecylenic acid and its ester prevents the latter from being awarded to catechol.
- the skin absorbability has been improved by introducing an ester derivative of perdecylenic acid and a zz group.
- it has a bristle-leakage action that is thought to be based on the pendecylenic acid group, and also has a surfactant action that is thought to be based on the
- the tyrosinase inhibitor II and the external preparation containing the inhibitor ij of the present invention which is effective for inducing decylenic acid or a salt thereof or an ester thereof, can be used as a chemical compound.
- As Sir, etc. it can be used for birth and field ⁇ 3 ⁇ 43 ⁇ 4.
- ascorbin mavi and / or ascorbic acid derivative # had excellent tyrosinase activity i action and melanin production i action.
- Ascorbic acid or ascorbic acid-inducing agent has been used as a melanin production inhibitor, but according to the present invention, ascorbine m3 ⁇ 4 / ⁇ or ascorbic acid-inducing agent # 3 ⁇ 4s, tyrosinase activity ⁇ ® ⁇ action and melanin production The fact that the I action is ⁇ ⁇ has become evident.
- ascorbic acid and z or ascorbic acid derivative can be inexpensively fibered and have high waviness.
- the external preparation containing the tyrosinase activity absorbing agent of the present invention containing ascorbic acid and z or an ascorbic acid derivative having the above-mentioned properties as an active ingredient is excellent in terms of its ability to reduce the production time and is excellent.
- Tyrosine synthase and melanin exert 3 ⁇ 4 ⁇ ® ⁇ action.
- tyrosinase-active thigh preparation of the present invention and the external preparation containing the key agent are useful in the fields of cosmetics and pharmaceuticals.
- ihX is a whitening fiber for improving white hair. It can be used as an agent for I ⁇ ⁇ or as an agent for easy treatment for anti-vitiligo treatment of ⁇ ⁇ .
- a compound having a hydroxyl group can be used as a raw material, and an enzymatic method of an esterified product having a high yield has been found.
- Toru's enzymatic ester exchange reaction was mainly performed in sexual media
- a specific enzyme it can be used in aprotic anaerobic media such as DMSO. It has been found that enzymatic esterification is possible. For this reason, a compound capable of dissolving a compound having a 7-nen group is used as a raw material in a solvent capable of dissolving a compound, thereby obtaining an esterified compound in a high yield.
- Agata and sucrose fatty acid esters were mainly obtained as a mixture of mono-, di-, and triester compounds in which the hydroxyl groups at the 6-, 6-, and 6'-positions were esterified.
- sucrose ester compound obtained by using the method of the present invention has excellent properties in terms of raw HW strength, solubility, emulsification, and ⁇ . , Shampoos, rinses, medicines, detergents, etc., can be used for! I.
- the method for weaving an esterified product of the present invention comprises the steps of weaving an esterified product using, as a raw material, a compound having a ⁇ -acid group, which is hardly soluble in a spine-containing medium, and a method for enzymatically reacting with an enzyme. It is a particularly effective means of weaving esterified products that require a reaction.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003272968A AU2003272968A1 (en) | 2002-10-10 | 2003-10-10 | Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same |
EP03754072A EP1550667A4 (en) | 2002-10-10 | 2003-10-10 | AGENTS FOR REGULATING TYROSINASE ACTIVITY, PROCESS FOR PRODUCING SAID AGENTS AND EXTERNAL PREPARATIONS CONTAINING THE SAME |
JP2005501026A JP4168170B2 (ja) | 2002-10-10 | 2003-10-10 | アルブチンエステル化合物及びその製造方法 |
US10/530,789 US7754864B2 (en) | 2002-10-10 | 2003-10-10 | Tyrosinase activity controlling agent, process for producing the same and external preparation containing the same |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-297040 | 2002-10-10 | ||
JP2002297040 | 2002-10-10 | ||
JP2002353403 | 2002-12-05 | ||
JP2002-353403 | 2002-12-05 | ||
JP2003117973 | 2003-04-23 | ||
JP2003-117973 | 2003-04-23 | ||
JP2003-294543 | 2003-08-18 | ||
JP2003294543 | 2003-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004033475A1 true WO2004033475A1 (ja) | 2004-04-22 |
Family
ID=32097012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013018 WO2004033475A1 (ja) | 2002-10-10 | 2003-10-10 | チロシナーゼ活性調整剤、その製法、及びそれを含有する外用剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7754864B2 (ja) |
EP (1) | EP1550667A4 (ja) |
JP (3) | JP4168170B2 (ja) |
AU (1) | AU2003272968A1 (ja) |
WO (1) | WO2004033475A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004331592A (ja) * | 2003-05-08 | 2004-11-25 | National Institute Of Advanced Industrial & Technology | 美白剤を配合した皮膚外用剤、石鹸、入浴剤、繊維処理剤、繊維 |
WO2006065852A1 (en) * | 2004-12-14 | 2006-06-22 | Access Business Group International Llc. | Methods of using grape seed extract to stimulate tyrosinase expression or melanin synthesis |
JP2007326791A (ja) * | 2006-06-06 | 2007-12-20 | Toyobo Co Ltd | ニキビ治療剤 |
JP2012219056A (ja) * | 2011-04-07 | 2012-11-12 | Hiroshima Univ | 皮膚外用剤 |
CN113151373A (zh) * | 2021-03-09 | 2021-07-23 | 武汉臻治生物科技有限公司 | 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1842530A1 (en) * | 2006-03-23 | 2007-10-10 | Cognis IP Management GmbH | Cosmetic composition comprising a combination of a sugar fatty acid ester with a plant extract of waltheria indica or pisum sativum for skin whitening |
US8273791B2 (en) * | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
JP2010155820A (ja) * | 2008-10-10 | 2010-07-15 | Hayashikane Sangyo Kk | 皮膚改善剤、血管改善剤、並びにこれらを含む医薬組成物、食品、飼料及び化粧品 |
CN103254256A (zh) * | 2013-01-07 | 2013-08-21 | 中国科学院昆明植物研究所 | 熊果苷糖酯衍生物在制备化妆品或药物中的应用 |
KR101628282B1 (ko) * | 2013-07-12 | 2016-06-08 | 주식회사 바이오랜드 | 알부틴 유도체를 함유하는 피부 미백용 조성물 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0477927A1 (en) * | 1990-09-26 | 1992-04-01 | Sunstar Kabushiki Kaisha | Sebaceous excitosecretory agent |
JPH04182415A (ja) * | 1990-11-19 | 1992-06-30 | Kaminomoto Honpo:Kk | 発毛・養毛促進剤 |
JPH05137994A (ja) * | 1991-11-19 | 1993-06-01 | Kanebo Ltd | 界面活性剤 |
JPH05294820A (ja) * | 1992-04-15 | 1993-11-09 | Takehiro Yoshikawa | 化粧料 |
JPH05320152A (ja) * | 1992-05-20 | 1993-12-03 | Kanebo Ltd | グラブリジン誘導体 |
US5346693A (en) * | 1991-07-19 | 1994-09-13 | L'oreal | Depigmenting cosmetic or dermatological composition containing arbutoside derivatives |
ES2141670A1 (es) * | 1997-12-15 | 2000-03-16 | Consejo Superior Investigacion | Procedimiento para la acilacion especifica enzimatica de un hidroxilo secundario de la sacarosa. |
JP2001151623A (ja) * | 1999-11-19 | 2001-06-05 | Shiseido Co Ltd | 皮膚外用剤 |
JP2001158730A (ja) * | 1999-12-03 | 2001-06-12 | Pola Chem Ind Inc | くすみ改善用の化粧料 |
US6306376B1 (en) * | 1997-07-08 | 2001-10-23 | L'oreal | Use of arbutin monoesters as depigmenting agents |
WO2001079241A1 (de) * | 2000-04-18 | 2001-10-25 | Henkel Kommanditgesellschaft Auf Aktien | Glykosid-ester und ihre herstellung sowie verwendung in kosmetika, pharmazeutika und nahrungs- bzw. futtermitteln |
JP2001316226A (ja) * | 2000-05-01 | 2001-11-13 | Nonogawa Shoji Kk | 頭髪化粧料 |
JP2001322990A (ja) * | 2000-05-12 | 2001-11-20 | Pola Chem Ind Inc | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 |
JP2002114670A (ja) * | 2000-10-02 | 2002-04-16 | Noevir Co Ltd | 抗菌性皮膚外用剤 |
JP2002275060A (ja) * | 2001-03-16 | 2002-09-25 | Ichimaru Pharcos Co Ltd | メラニン生成促進剤 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2638968B2 (ja) * | 1987-11-06 | 1997-08-06 | 住友化学工業株式会社 | 置換ピラゾールカルボン酸誘導体、それを有効成分とする農園芸用殺菌剤および中間体 |
JPH01250308A (ja) * | 1988-03-31 | 1989-10-05 | Sansho Seiyaku Co Ltd | 白髪防止剤 |
JPH02129113A (ja) * | 1988-11-09 | 1990-05-17 | Sansho Seiyaku Co Ltd | 外用剤 |
JPH0578222A (ja) | 1991-05-01 | 1993-03-30 | Sansho Seiyaku Co Ltd | 白髪防止剤 |
JPH0656815A (ja) | 1992-08-04 | 1994-03-01 | Kanebo Ltd | α−トコフェリル−10−ウンデシレート |
JPH06305940A (ja) | 1993-04-22 | 1994-11-01 | Lion Corp | 毛髪用組成物 |
JP3574495B2 (ja) | 1994-03-31 | 2004-10-06 | 臼杵製薬株式会社 | 頭髪料 |
JPH07285874A (ja) | 1994-04-14 | 1995-10-31 | Kunio Tsuji | メラニン生成促進剤及びこれを含有する頭髪用化粧料 |
JPH07316048A (ja) | 1994-05-24 | 1995-12-05 | Kunio Tsuji | メラニン生成促進剤及びこれを含有する頭髪用化粧料 |
JPH089987A (ja) | 1994-07-05 | 1996-01-16 | Lion Corp | 糖脂肪酸エステルの製造方法 |
JP2913010B2 (ja) | 1995-03-09 | 1999-06-28 | 農林水産省食品総合研究所長 | 有機溶媒可溶化リパーゼを用いる糖質−脂肪酸複合体の製造方法 |
JPH09271387A (ja) | 1996-04-04 | 1997-10-21 | Lion Corp | 糖脂肪酸エステルの製造方法 |
JPH10139622A (ja) * | 1996-11-06 | 1998-05-26 | Kanebo Ltd | 荒肌改善剤 |
JP3604258B2 (ja) | 1997-05-30 | 2004-12-22 | 株式会社ノエビア | メラニン産生促進剤並びにこれを含有する皮膚外用剤 |
JP3660485B2 (ja) | 1997-10-17 | 2005-06-15 | 花王株式会社 | 白髪防止剤 |
JPH11189541A (ja) | 1997-12-26 | 1999-07-13 | Eag Kk | メラニン産生不全症治療剤 |
JP2001278752A (ja) | 2000-01-28 | 2001-10-10 | Kanebo Ltd | 毛髪化粧料 |
JP4869469B2 (ja) | 2000-04-10 | 2012-02-08 | 丸善製薬株式会社 | メラニン産生促進剤及び白髪改善剤 |
JP4504520B2 (ja) | 2000-06-26 | 2010-07-14 | 花王株式会社 | メラニン産生促進剤 |
JP2002047130A (ja) | 2000-07-26 | 2002-02-12 | Kao Corp | メラニン産生促進剤 |
JP2002114669A (ja) | 2000-10-02 | 2002-04-16 | Noevir Co Ltd | 抗菌性皮膚洗浄料 |
-
2003
- 2003-10-10 JP JP2005501026A patent/JP4168170B2/ja not_active Expired - Fee Related
- 2003-10-10 AU AU2003272968A patent/AU2003272968A1/en not_active Abandoned
- 2003-10-10 EP EP03754072A patent/EP1550667A4/en not_active Withdrawn
- 2003-10-10 WO PCT/JP2003/013018 patent/WO2004033475A1/ja active Application Filing
- 2003-10-10 US US10/530,789 patent/US7754864B2/en not_active Expired - Fee Related
-
2008
- 2008-05-16 JP JP2008129894A patent/JP4892660B2/ja not_active Expired - Fee Related
- 2008-05-16 JP JP2008129915A patent/JP4803557B2/ja not_active Expired - Fee Related
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0477927A1 (en) * | 1990-09-26 | 1992-04-01 | Sunstar Kabushiki Kaisha | Sebaceous excitosecretory agent |
JPH04182415A (ja) * | 1990-11-19 | 1992-06-30 | Kaminomoto Honpo:Kk | 発毛・養毛促進剤 |
US5346693A (en) * | 1991-07-19 | 1994-09-13 | L'oreal | Depigmenting cosmetic or dermatological composition containing arbutoside derivatives |
JPH05137994A (ja) * | 1991-11-19 | 1993-06-01 | Kanebo Ltd | 界面活性剤 |
JPH05294820A (ja) * | 1992-04-15 | 1993-11-09 | Takehiro Yoshikawa | 化粧料 |
JPH05320152A (ja) * | 1992-05-20 | 1993-12-03 | Kanebo Ltd | グラブリジン誘導体 |
US6306376B1 (en) * | 1997-07-08 | 2001-10-23 | L'oreal | Use of arbutin monoesters as depigmenting agents |
ES2141670A1 (es) * | 1997-12-15 | 2000-03-16 | Consejo Superior Investigacion | Procedimiento para la acilacion especifica enzimatica de un hidroxilo secundario de la sacarosa. |
JP2001151623A (ja) * | 1999-11-19 | 2001-06-05 | Shiseido Co Ltd | 皮膚外用剤 |
JP2001158730A (ja) * | 1999-12-03 | 2001-06-12 | Pola Chem Ind Inc | くすみ改善用の化粧料 |
WO2001079241A1 (de) * | 2000-04-18 | 2001-10-25 | Henkel Kommanditgesellschaft Auf Aktien | Glykosid-ester und ihre herstellung sowie verwendung in kosmetika, pharmazeutika und nahrungs- bzw. futtermitteln |
JP2001316226A (ja) * | 2000-05-01 | 2001-11-13 | Nonogawa Shoji Kk | 頭髪化粧料 |
JP2001322990A (ja) * | 2000-05-12 | 2001-11-20 | Pola Chem Ind Inc | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 |
JP2002114670A (ja) * | 2000-10-02 | 2002-04-16 | Noevir Co Ltd | 抗菌性皮膚外用剤 |
JP2002275060A (ja) * | 2001-03-16 | 2002-09-25 | Ichimaru Pharcos Co Ltd | メラニン生成促進剤 |
Non-Patent Citations (7)
Title |
---|
ARMESTO, NURIA ET AL: "Regioselective enzymatic acylation of methyl shikimate. Influence of acyl chain length and solvent polarity on enzyme specificity", J. ORG. CHEM., vol. 67, no. 14, 12 June 2002 (2002-06-12), pages 4978 - 4981, XP002974845 * |
ISHIHARA KOJI. ET AL: "A chemoenzymatic synthesis of aromatic carboxylic acid vinyl esters", JOURNAL OF MOLECULAR CATALYSIS B:ENZYMATIC, vol. 7, 1999, pages 307 - 310, XP002974844 * |
LILJEBLAD, ARTO. ET AL: "Enzymatic methods for the preparation of enantiopure malic and aspartic acid derivatives in organic solvents", TETRAHEDRON: ASYMMETRY, vol. 10, 1999, pages 4405 - 4415, XP004186386 * |
NAKAJIMA N. ET AL: "Lipase-catalyzed direct and regioselective acylation of flavonoid glucoside for mechanistic investigation of stable plant pigments", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 87, no. 1, 1999, pages 105 - 107, XP001015236 * |
PEDERSEN, NINFA RANGEL, ET AL: "Efficient transesterification of sucrose catalysed by the metalloprotease thermolysin in dimethylsulfoxide", FEBS LETTERS, vol. 519, no. 13, 22 May 2002 (2002-05-22), pages 181 - 184, XP004356844 * |
See also references of EP1550667A4 * |
VEROTTA L. ET AL: "Polyphenolic glycosides from african proteaceae", JOURNAL OF NATURAL PRODUCTS, vol. 62, no. 11, 1999, pages 1526 - 1531, XP002974843 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004331592A (ja) * | 2003-05-08 | 2004-11-25 | National Institute Of Advanced Industrial & Technology | 美白剤を配合した皮膚外用剤、石鹸、入浴剤、繊維処理剤、繊維 |
WO2006065852A1 (en) * | 2004-12-14 | 2006-06-22 | Access Business Group International Llc. | Methods of using grape seed extract to stimulate tyrosinase expression or melanin synthesis |
US7875302B2 (en) | 2004-12-14 | 2011-01-25 | Access Business Group International Llc | Methods of using grape seed extract to stimulate tyrosinase gene expression |
JP2007326791A (ja) * | 2006-06-06 | 2007-12-20 | Toyobo Co Ltd | ニキビ治療剤 |
JP2012219056A (ja) * | 2011-04-07 | 2012-11-12 | Hiroshima Univ | 皮膚外用剤 |
CN113151373A (zh) * | 2021-03-09 | 2021-07-23 | 武汉臻治生物科技有限公司 | 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用 |
CN113151373B (zh) * | 2021-03-09 | 2023-07-04 | 武汉臻治生物科技有限公司 | 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP1550667A4 (en) | 2008-02-20 |
JP2008200054A (ja) | 2008-09-04 |
JP4168170B2 (ja) | 2008-10-22 |
JPWO2004033475A1 (ja) | 2006-02-23 |
JP4803557B2 (ja) | 2011-10-26 |
AU2003272968A1 (en) | 2004-05-04 |
JP4892660B2 (ja) | 2012-03-07 |
US7754864B2 (en) | 2010-07-13 |
JP2008214361A (ja) | 2008-09-18 |
EP1550667A1 (en) | 2005-07-06 |
AU2003272968A8 (en) | 2004-05-04 |
US20060052318A1 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4713832B2 (ja) | 2−O−(β−D−グルコピラノシル)アスコルビン酸、その製造法、およびそれを含有する組成物を含む食品ならびに化粧品 | |
Zhang et al. | Effects of extraction methods on the antioxidant activities of polysaccharides obtained from Flammulina velutipes | |
Mellou et al. | Biocatalytic preparation of acylated derivatives of flavonoid glycosides enhances their antioxidant and antimicrobial activity | |
JP3958968B2 (ja) | 皮膚外用剤及び美白剤 | |
EP1500645B1 (en) | Astaxanthin medium-chain fatty acid ester, process for producing the same and composition containing the ester | |
WO2008018448A1 (fr) | Activateur comprenant un bio-tensioactif comme ingrédient actif, un mannosyl érythritol lipide et son procédé de préparation | |
WO2004033475A1 (ja) | チロシナーゼ活性調整剤、その製法、及びそれを含有する外用剤 | |
KR102052874B1 (ko) | 배당체 화합물 | |
JP2005132842A (ja) | 抗酸化特性を有する組成物 | |
WO2004094369A2 (en) | Stabilized derivatives of ascorbic acid | |
KR100586814B1 (ko) | 멜라닌 생합성 저해 활성을 갖는 테레인 화합물 및 그의제조방법 | |
CN101450047A (zh) | 一种从黑桑中提取的化合物作为酪氨酸酶抑制剂的用途 | |
JP6143167B2 (ja) | 小眼球症関連転写因子抑制剤、メラニン産生抑制剤、化粧品組成物及び抗ガン剤 | |
JP5055540B2 (ja) | チロシナーゼ阻害剤 | |
JP2003277271A (ja) | 抗癌剤 | |
Tai et al. | Highly efficient and regioselective production of an erythorbic acid glucoside using cyclodextrin glucanotransferase from Thermoanaerobacter sp. and amyloglucosidase | |
JP5942185B2 (ja) | メラニン抑制及びmitf抑制作用を有する美白用組成物及び抗ガン剤 | |
JP2012025724A (ja) | 癌増殖抑制剤 | |
JP7325779B1 (ja) | Cd39発現促進剤 | |
CN101143882A (zh) | 酪氨酸酶活性调整剂、其制法及含该调整剂的外用制剂 | |
KR101038022B1 (ko) | 신규 당 화합물 | |
KR100550818B1 (ko) | 티로시나제 저해활성을 지닌 상황버섯 추출물 또는그로부터 분리한 화합물들을 함유하는 조성물 | |
JP2009132644A (ja) | 面皰炎症抑制剤及びこれを含む皮膚外用剤 | |
EP3984628A1 (en) | Acid type sophorolipid-containing composition which is suppressed in browning | |
KR20220047177A (ko) | (1r,4s,6s)-1,6-디하이록시-2-메텐을 이용한 항염증용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003754072 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006052318 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005501026 Country of ref document: JP Ref document number: 10530789 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A12379 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003754072 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10530789 Country of ref document: US |